Navigation Links
TPI to Host Fiscal Year 2011 Earnings Conference Call on Tuesday, September 27, 2011 at 9:00 a.m. ET
Date:9/21/2011

CHENGDU, China, Sept. 21, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients (API), today announced that the earnings conference call for the fiscal year 2011 ending June 30, 2011 will be held at 9:00 a.m. Eastern Time on Tuesday, September 27, 2011.

Interested parties may access the call by dialing 1-877-941-2068 (U.S.) or 1-480-629-9712 (International).

The conference ID is 4474328. It is advisable to dial in approximately 5 minutes prior to the start of the call.

A replay will be available by calling 1-877-870-5176 or 1-858-384-5517 (International) from 09/27/2011 at 12:00 noon Eastern Time to 10/11/2011 at 11:59 pm Eastern Time.

Replay Pin Number:  4474328

This call is being web cast by ViaVid Broadcasting and can be accessed at the following link: http://viavid.net/dce.aspx?sid=00008D3F

About TPIHeadquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and other pharmaceuticals. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.

For more information about TPI, please visit:  http://www.tianyinpharma.com.

Safe Harbor StatementThe Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.For more information, please contact:Investors Contact: ir@tianyinpharma.com Web:   http://www.tianyinpharma.com Tel: +86-28-8551-6696 (Chengdu, China)+86 134-36-550011 (China)Address:23rd Floor Unionsun Yangkuo PlazaNo. 2, Block 3, South Renmin RoadChengdu, 610041China
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2011 Fourth Quarter Results; Teleconference and Webcast to be held on September 22, 2011
2. China Botanic Pharmaceutical Reports Third-Quarter Fiscal Year 2011 Results
3. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2011 on September 12, 2011
4. China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2012
5. China Cord Blood Corporation to Report First Quarter Fiscal 2012 Financial Results
6. Biodel Reports Third Quarter Fiscal Year 2011 Financial Results
7. K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call
8. China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011
9. China Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2011 Financial Results
10. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
11. SeraCare Reports Second Quarter Fiscal Year 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Aethlon Medical, Inc. (Nasdaq: AEMD ... validated the ability of the Aethlon Hemopurifier® to capture ... in immune-suppressed sepsis patients and also contribute to organ ... of the study was to validate the in ... and Herpes Simplex virus 1 (HSV1) by the Hemopurifier®. ...
(Date:2/22/2017)... SAN DIEGO , Feb. 22, ... (OTCQB:CELZ) announced today expansion of its translational research ... product through establishment of laboratory facilities in San ... the San Diego BioLabs facility, a biotechnology incubator ... and Sanofi. In November 2016, the ...
(Date:2/21/2017)... , Feb. 21, 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" ... and operational results for the three months ended December 31, ... -based life sciences and diagnostics company that develops and ... ... continue to build on the commercial milestones achieved in fiscal ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... and development (R&D), today announced the establishment of Genedata Limited as a new ... Teburi, a recognized expert in life science informatics. Creating the UK subsidiary reinforces ...
Breaking Biology Technology:
(Date:2/21/2017)... LONDON , February 21, 2017 ... um 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr ... es einige Hindernisse zu überwinden gilt, um diese Prognose ... ... unter anderem die Mobilisierung der finanziellen Mittel für die ...
(Date:2/14/2017)...  Wake Forest Baptist Medical Center today announced Julie Ann ... officer (CEO). Freischlag joins the medical center on May ... M.D., who last year announced that he would transition ... leading it since 2008.   As CEO, ... Baptist,s academic health system, which includes Wake Forest School ...
(Date:2/13/2017)... WASHINGTON , Feb. 13, 2017 Former ... U.S. Senate Judiciary Committee, Janice Kephart of ... regarding President Donald Trump,s "Executive Order: Protecting ... States" (Jan. 27, 2017):  "As President Trump,s ... 9th Circuit has now essentially banned the travel ban, ...
Breaking Biology News(10 mins):